

Special Issue

Recent Advances in Peptide-Based Vaccines

Message from the Guest Editor

Using entire organism-based vaccines has various potential disadvantages such as induction of allergy, autoimmunity, and antibody-dependent enhancement in some cases. On the other hand, peptide-based vaccines are more specific, safe, and cost-effective. These peptides can be engineered and manufactured to resemble specific immunogenic antigens of pathogenic agents. In addition, peptide-based vaccines have attracted much interest in the development of novel vaccines to treat certain chronic diseases such as Alzheimer's disease and cancer, providing protective responses and limiting the administration of therapeutics. However, peptide-based vaccines have a low immunogenic effect and therefore need potent immune-stimulating adjuvants and specialized delivery carriers such as nanoparticles or fused to immunogenic carriers. This Special Issue focuses on the recent advances in peptide-based vaccines, including peptide identification, immunogenic effect and adjuvant agents, and selected delivery systems.

Guest Editor

Dr. Hussin Rothan

Department of Biology, Georgia State University, Atlanta, GA 30302, USA

Deadline for manuscript submissions

closed (15 October 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/52491

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).